Order Article Reprints

Wang H-W, Chuang P-H, Su W-P, Kao J-T, Hsu W-F, Lin C-C, Huang G-T, Lin J-T, Lai H-C, Peng C-Y. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2021; 13(15):3758. https://doi.org/10.3390/cancers13153758

Wang, Hung-Wei, Po-Heng Chuang, Wen-Pang Su, Jung-Ta Kao, Wei-Fan Hsu, Chun-Che Lin, Guan-Tarn Huang, Jaw-Town Lin, Hsueh-Chou Lai, and Cheng-Yuan Peng. 2021. "On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma" Cancers 13, no. 15: 3758. https://doi.org/10.3390/cancers13153758

Wang, H.-W., Chuang, P.-H., Su, W.-P., Kao, J.-T., Hsu, W.-F., Lin, C.-C., Huang, G.-T., Lin, J.-T., Lai, H.-C., & Peng, C.-Y. (2021). On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 13(15), 3758. https://doi.org/10.3390/cancers13153758